Management of pertussis in adolescents and adults: The role of a reduced-antigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine

Journal of Preventive Medicine and Hygiene

Volumn 46, Issue 1, 2005, Pages 33-41

  Di Pasquale, A ^a   Wolter, J ^b   Schuerman, L ^b  

^a GSK   (Italy)

^b GSK   (Belgium)

Author keywords

Adolescent; Pertussis; Vaccination

Indexed keywords

ADT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; LEDERJECT; UNCLASSIFIED DRUG;

ADOLESCENT DISEASE; ADULT DISEASE; ANTIBODY RESPONSE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CLINICAL TRIAL; DIPHTHERIA; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEVER; HEALTH ECONOMICS; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INJECTION PAIN; PERTUSSIS; REVIEW; TETANUS; VACCINATION;

EID: 17444422841     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. World Health Organization. Pertussis vaccine [online]. Available from URL: http://www.who.int/vaccines/en/pertussis.shtml [Accessed August 23 2004].
2. Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992;14:708-19.
3. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999;28:1230-7.
4. Centers for Disease Control and Prevention. Pertussis - United States, 1997-2000. MMWR 2002;51:73-6.
5. Health Canada. National Consensus Conference on Pertussis. Canada Communicable Diseases Report 2003;2953:1-33.
6. Strebel P, Nordin J, Edwards K, Hunt J, Besser J, Burns S, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001;183:1353-9.
7. Menzies R, Wang H, McIntyre P. Has pertussis increase in NSW over the past decade? An evaluation using hospitalisation and mortality data versus notifications 1988-2002. NSW Public Health Bulletin 2003;14:71-6.
8. EUVAC.NET. A Surveillance Community Network for Vaccine Preventable Infectious Diseases [online] Available from URL: http://www.ssi.dk/euvac/ [Accessed August 23 2004].
9. EUVAC-NET Pertussis surveillance. Final Report [online]. Available from URL: www.euvac.net [Accessed August 232004].
10. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003;290:2968-75.
11. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 2003;22:628-34.
12. Baron S, Njamkepo E, Grimprel E, Begue P, Desenclos JC, Drucker J, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994:thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998;17:412-8.
13. Halperin SA, Wang EE, Law B, Mills E, Morris R, Dery P, et al. Epidemiological features of pertussis in hospitalized patients in Canada. 1991-1997:report of the Immunisation Monitoring Program-Active (IMPACT). Clin Infect Dis 1999;28:1238-43.
14. Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004;23:246-52.
15. Garcia-Miguel MJ, Campins M, Roca J, Moraga F, Martinez-Cortes F, Gene A, et al. Bordetella pertussis infection in infants and their household contacts. Preliminary results of a prospective epidemiological study. In: 22nd Annual Meeting of the European Society for Paediatric Infectious Diseases 2004 May 26-28; Tampere, Finland.
16. Wirsing von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002;2:744-50.
17. Wharton M. Prevention of pertussis among adolescents by vaccination: taking action on what we know and acknowledging what we do not know. Clin Infect Dis 2004;39:29-30.
18. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 1997;100:E10.
19. Deeks S, De Serres G, Boulianne N, Duval B, Rochette L, Dery P, et al. Failure of physicians to consider the diagnosis of pertussis in children. Clin infect Dis 1999;28:840-6.
20. Crowcroft NS, Booy R, Harrison T, Spicer L, Britto J, Mok Q, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 2003;88:802-6.
21. Esposito S, Agliardi T, Giammanco A, Faldella G, Cascio A, Bosis S, et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun 2001;69:4516-20.
22. Campins-Martí M, Cheng HK, Forsoyth K, Guiso N, Halperin S, Huang L-M, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2002;20:641-6.
23. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004;22:3154-65.
24. Hethcote HW, Horby P, McIntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 2004;22:2181-91.
25. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 2004;190:535-44.
26. GlaxoSmithKline. Boostrix™ Monograph.
27. Minh NNT, He Q, Ramalho A, Kaufhold A, Viljanen MK, Arvilommi H, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999;104:e70.
28. Van der Wielen M, Van Damme P, Joossens E, Francois G, Meurice F, Ramalho A. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000;18:2075-82.
29. Turnbull FM, Heath TC, Jalaludin BB, Burgess MA, Ramalho AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000;19:628-36.
30. Van Damme P, Burgess M. Immunogenicity of a combined diphteria-tetanus- acellular pertussis vaccine in adults. Vaccine 2004;22:305-8.
31. Zepp F, Cheuvart B, Wolter JM. Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (DTPA) in preschool-aged children. In: 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2003 April 9-11; Taormina, Sicily.
32. Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, et al. Reactogenicity and immunogenicitv of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003;21:4194-200.
33. Ward J. Acellular pertussis vaccine in adolescents and adults. 41 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2001, (abstr. n. 1291).
34. Di Pasquale A. Boostrix un novo vaccino combinato per i richiami di difterite tetano e pertosse. Journal of Preventive Medicine and Hygiene 2002;45(Suppl I):S20-4.
35. Edelman KJ, He Q, Makinen JP, Haanpera MS, Nguyen Tran Minh N, Schuerman L, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 2004;39:179-85.
36. Hoel T, Wolter JM, Schuerman LM. The use of a reduced-antigen, diphtheria-tetanus-pertussis vaccine for wound management in adults. In: 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2003 April 9-11; Taormina, Sicily.
37. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004;39:20-8.
38. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 2002;20:1316-30.
39. Impfempfehlungen der Standigen Impfkommission (STIKO) am Robert Koch-Institut/Stand. Epidemiologisches Bull 2000;2:9-20.
40. Heininger U. New immunisation recommendations in Germany. Arch Dis Child 2002;86:64.
41. Il nuovo calendario delle vaccinazioni obbligatorie e raccomandate per l'età evolutiva. Gazzetta Ufficiale 1999;87.
42. th Ed. 2003.
43. Health Canada. Prevention of pertussis in adolescents and adults. Canada Communicable Diseases Report 2003;29:1-12.